Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally.
Torrent Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹2,979.60|
|52 Week High||₹2,311.30|
|52 Week Low||₹3,248.00|
|1 Month Change||-2.28%|
|3 Month Change||-1.09%|
|1 Year Change||10.22%|
|3 Year Change||85.77%|
|5 Year Change||90.29%|
|Change since IPO||4,667.36%|
Recent News & Updates
|500420||IN Pharmaceuticals||IN Market|
Return vs Industry: 500420 underperformed the Indian Pharmaceuticals industry which returned 21.4% over the past year.
Return vs Market: 500420 underperformed the Indian Market which returned 65.9% over the past year.
Stable Share Price: 500420 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 500420's weekly volatility (3%) has been stable over the past year.
About the Company
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, women healthcare, diabetology, pain management, gynecology, oncology, and anti-infective, as well as provides vitamins, minerals, and nutrients. The company also offers contract manufacturing services.
Torrent Pharmaceuticals Fundamentals Summary
|500420 fundamental statistics|
Is 500420 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|500420 income statement (TTM)|
|Cost of Revenue||₹21.99b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 26, 2021
|Earnings per share (EPS)||74.51|
|Net Profit Margin||15.60%|
How did 500420 perform over the long term?See historical performance and comparison
1.0%Current Dividend Yield
Is Torrent Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 500420 (₹2979.6) is trading above our estimate of fair value (₹2211.52)
Significantly Below Fair Value: 500420 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 500420 is poor value based on its PE Ratio (40x) compared to the Indian Pharmaceuticals industry average (25.6x).
PE vs Market: 500420 is poor value based on its PE Ratio (40x) compared to the Indian market (21.9x).
Price to Earnings Growth Ratio
PEG Ratio: 500420 is poor value based on its PEG Ratio (2.3x)
Price to Book Ratio
PB vs Industry: 500420 is overvalued based on its PB Ratio (8.6x) compared to the IN Pharmaceuticals industry average (3.2x).
How is Torrent Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 500420's forecast earnings growth (17.2% per year) is above the savings rate (6.7%).
Earnings vs Market: 500420's earnings (17.2% per year) are forecast to grow slower than the Indian market (19.1% per year).
High Growth Earnings: 500420's earnings are forecast to grow, but not significantly.
Revenue vs Market: 500420's revenue (11.3% per year) is forecast to grow slower than the Indian market (12.8% per year).
High Growth Revenue: 500420's revenue (11.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 500420's Return on Equity is forecast to be high in 3 years time (22.4%)
How has Torrent Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 500420 has high quality earnings.
Growing Profit Margin: 500420's current net profit margins (15.6%) are higher than last year (14.2%).
Past Earnings Growth Analysis
Earnings Trend: 500420's earnings have grown by 3.5% per year over the past 5 years.
Accelerating Growth: 500420's earnings growth over the past year (11.6%) exceeds its 5-year average (3.5% per year).
Earnings vs Industry: 500420 earnings growth over the past year (11.6%) underperformed the Pharmaceuticals industry 35.8%.
Return on Equity
High ROE: 500420's Return on Equity (21.6%) is considered high.
How is Torrent Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: 500420's short term assets (₹55.2B) exceed its short term liabilities (₹48.9B).
Long Term Liabilities: 500420's short term assets (₹55.2B) exceed its long term liabilities (₹33.5B).
Debt to Equity History and Analysis
Debt Level: 500420's debt to equity ratio (84.4%) is considered high.
Reducing Debt: 500420's debt to equity ratio has increased from 70.1% to 84.4% over the past 5 years.
Debt Coverage: 500420's debt is well covered by operating cash flow (40.8%).
Interest Coverage: 500420's interest payments on its debt are well covered by EBIT (5.8x coverage).
What is Torrent Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 500420's dividend (1.01%) is higher than the bottom 25% of dividend payers in the Indian market (0.33%).
High Dividend: 500420's dividend (1.01%) is low compared to the top 25% of dividend payers in the Indian market (1.38%).
Stability and Growth of Payments
Stable Dividend: 500420's dividend payments have been volatile in the past 10 years.
Growing Dividend: 500420's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (47%), 500420's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 500420's dividends in 3 years are forecast to be well covered by earnings (30.3% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Samir Mehta (57 yo)
Mr. Samir Uttamlal Mehta, B.Com., MBA serves as a Managing Director of Torrent Pharmaceuticals Limited since 1989. Mr. Mehta served as Managing Director of Torrent Power Limited. Mr. Mehta has been associa...
CEO Compensation Analysis
Compensation vs Market: Samir's total compensation ($USD2.66M) is above average for companies of similar size in the Indian market ($USD812.90K).
Compensation vs Earnings: Samir's compensation has been consistent with company performance over the past year.
Experienced Board: 500420's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Torrent Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: Torrent Pharmaceuticals Limited
- Ticker: 500420
- Exchange: BSE
- Founded: 1959
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹504.216b
- Shares outstanding: 169.22m
- Website: https://www.torrentpharma.com
Number of Employees
- Torrent Pharmaceuticals Limited
- Torrent House
- Off. Ashram Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:15|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.